DLD Asset Management LP acquired a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 27,096 shares of the exchange traded fund’s stock, valued at approximately $2,715,000.
A number of other institutional investors also recently bought and sold shares of the business. Capital A Wealth Management LLC purchased a new position in shares of SPDR S&P Biotech ETF during the second quarter worth about $26,000. Johnson Financial Group Inc. purchased a new stake in SPDR S&P Biotech ETF during the 2nd quarter valued at approximately $31,000. Twin Peaks Wealth Advisors LLC purchased a new stake in SPDR S&P Biotech ETF during the 2nd quarter valued at approximately $32,000. Davis Capital Management acquired a new stake in SPDR S&P Biotech ETF during the 3rd quarter worth approximately $35,000. Finally, Halbert Hargrove Global Advisors LLC acquired a new stake in SPDR S&P Biotech ETF during the 3rd quarter worth approximately $40,000.
SPDR S&P Biotech ETF Trading Up 0.1%
Shares of XBI stock opened at $124.00 on Monday. The company has a market capitalization of $8.29 billion, a P/E ratio of 11.47 and a beta of 0.93. The business’s 50 day moving average is $125.17 and its two-hundred day moving average is $114.12. SPDR S&P Biotech ETF has a twelve month low of $66.66 and a twelve month high of $132.09.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
See Also
- Five stocks we like better than SPDR S&P Biotech ETF
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- What a Former CIA Agent Knows About the Coming Collapse
- Elon Musk already made me a “wealthy man”
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
